# US 2026/0062670 A1 · Method for treating and modelling hearing loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062670 A1
- Document ID: US20260062670A1
- Status: Published application
- Kind: A1
- Application number: 19/386,308
- Filed: 2025-11-12
- Published: 2026-03-05
- Earliest claimed: 2018-05-04
- Assignees: Mackay Medical College
- Applicants: Mackay Medical College
- Inventors: Yi-Chao Hsu
- Web page: https://patentgrep.com/patent/US20260062670A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2501/998: Proteins not provided for elsewhere
- C12N 2506/45: from artificially induced pluripotent stem cells
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method for treating hearing loss in a subject in need thereof is provided. The method includes providing a combination of transcription factors to induce generation of a hair cell-like cell, thereby treating the hearing loss in the subject. The generated hair cell-like cells exhibit characteristic of mature functional cells that is useful in cell replacement therapy for autologous transplantation.

## Claims

### Claim 1

A method for treating hearing loss in a subject in need thereof, comprising:
administering a set of nucleic acids or a set of polypeptides to an inner ear of the subject in need thereof; and
inducing generation of a mature hair cell-like cell by the set of nucleic acids or the set of polypeptides;
wherein the set of nucleic acids comprises a first nucleic acid encoding ATOH1, a second nucleic acid encoding RFX1, and a third nucleic acid encoding RFX3, or wherein the set of polypeptides comprises ATOH1, RFX1, and RFX3.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the set of nucleic acids or the set of polypeptides increases expression levels of RFX1 and RFX3 in a cell at an otic progenitor stage in vivo.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the generation of the mature hair cell-like cell is driven by differentiation of an otic progenitor cell in the inner ear of the subject.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the subject has myoclonus epilepsy associated with ragged-red fibres syndrome or mitochondrial mutation-associated hearing loss.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the subject suffers from sensorineural hearing loss, or wherein the hearing loss involves degeneration or loss of inner ear hair cells.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mature hair cell-like cell has stereociliary bundles on the cell surface thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the mature hair cell-like cell serves as a modelling system for the hearing loss.

### Claim 8

A kit for treating hearing loss, comprising a set of expression vectors including:
a first expression vector having a first nucleic acid encoding ATOH1;
a second expression vector having a second nucleic acid encoding RFX1; and
a third expression vector having a third nucleic acid encoding RFX3,
wherein the set of expression vectors allows production of transcription factors comprising ATOH1, RFX1, and RFX3 in a host cell or in vivo.

### Claim 9 (depends on 8)

The kit according to claim 8, wherein the set of expression vectors increases expression levels of RFX1 and RFX3 in a cell at an otic progenitor stage.

### Claim 10 (depends on 8)

The kit according to claim 8, wherein the host cell is an otic progenitor cell derived from a human induced pluripotent stem cell.

### Claim 11 (depends on 8)

The kit according to claim 8, wherein at least one of the first, second and third expression vectors is a lentiviral vector, an adenoviral vector, a retroviral vector, an adeno-associated virus (AAV) vector or a Sendai viral vector.
